Hypertension in black South Africans

Journal of Human Hypertension

Volumn 13, Issue 2, 1999, Pages 97-103

  Seedat, Y K ^a  

^a UNIVERSITY OF NATAL   (South Africa)

Author keywords

Black South Africans; Clinical features; Patho physiology; Treatment

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CARVEDILOL; CLONIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; IRBESARTAN; LABETALOL; LOSARTAN; METHYLDOPA; NIFEDIPINE; PRAZOSIN; PROPRANOLOL; RESERPINE; SOTALOL; THIAZIDE DIURETIC AGENT; VALSARTAN; VASODILATOR AGENT; VERAPAMIL;

BLOOD PRESSURE; BRAIN HEMORRHAGE; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DEPRESSION; ENDOCRINE FUNCTION; ENVIRONMENTAL FACTOR; ETHNIC GROUP; GENETICS; HEART FUNCTION; HUMAN; HYPERTENSION; KIDNEY; MALIGNANT HYPERTENSION; NEGRO; NOSE CONGESTION; PREVALENCE; RACE DIFFERENCE; RAUWOLFIA; REVIEW; SOCIAL STATUS; SOUTH AFRICA; UREMIA; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; CHILD; CLINICAL TRIAL; FEMALE; INCIDENCE; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTOR; SEX RATIO;

ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGE DISTRIBUTION; AGED; ANTIHYPERTENSIVE AGENTS; CHILD; CLINICAL TRIALS; FEMALE; HUMANS; HYPERTENSION; INCIDENCE; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; SEX DISTRIBUTION; SOUTH AFRICA;

EID: 0032987973     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000773     Document Type: Review

References (79)

1. Nissinen A, Bothig S, Granroth H, Lopez AD. Hypertension in developing countries. World Health Stat Q 1988; 41: 141-154.
2. Akinkugbe OO. World epidemiology of hypertension in blacks. In: Hall WD, Saunders E, Shulman N (eds). Hypertension in Blocks: Epidemiology, Pathophysiology and Treatment. Year Book Medical Publishers: Chicago, 1985, pp 13-16.
3. Seedat YK. Race, environment and blood pressure: the South African experience. J Hypertens 1983; 1: 7-12.
4. Burt VL et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population: data from the health examinations surveys, 1960 to 1991. Hypertension 1995; 26: 60-69.
5. Weiss MM, Prusmack JJ. Essential hypertension in the Negro. Am Med Sci 1938; 195: 510-516.
6. Seedat YK, Pillay N, Marcoyannopoulou-Fojas H. Myocardial infarction in the African hypertensive patient. Am Heart J 1977; 94: 388-390.
7. Isaacson C. The changing pattern of heart disease in South African blacks. S Afr Med J 1977; 52: 793-798.
8. Weissberg PL, Woods KL, West MJ, Beevers DG. Genetic: and ethnic influences on the distribution of sodium and potassium in normotensive and hypertensive subjects. J Clin Hypertens 1987; 3: 20-25.
9. Touyz RM, Milne FJ, Seftel HC, Reinach SG. Magnesium, calcium, sodium and potassium status in normotensive and hypertensive Johannesburg residents. S Afr Med J 1987; 72: 377-381.
10. Hennessy JF, Ober KP. Racial differences in erythrocyte ion transport. Ann Clin Lab Sci 1982; 12: 35-41.
11. Hoosen S, Seedat YK, Bhigjee AL. A study of urinary and intracellular sodium and potassium, renin, aldosterone, and hypertension in blacks and Indians in Natal. Cardiovasc Drugs Ther 1990; 4: 363-365.
12. Zinner SH et al. Familial aggregation of urinary kallikrein concentration in childhood: relation to blood pressure, race and urinary electrolytes. Am J Epidemiol 1976; 104: 124-132.
13. Savage DD, Watkins LO, Grim CE, Kumanyika SK. Hypertension in black populations. In: Laragh JH, Brenner BM (eds). Hypertension: Pathophysiology, Diagnosis and Management. Raven Press: New York, 1990, 1st edn, pp 1837-1852.
14. Berenson GS et al. Creatinine clearance, electrolytes, and plasma renin activity related to blood pressure of white and black children - the Bogalusa Study. J Clin Med 1979; 93: 535-548.
15. Hohn AR et al. Childhood familial and racial differences in physiologic and biochemical factors related to hypertension. Hypertension 1983; 5: 56-70.
16. Miller JZ, Grim CE. Heritability of blood pressure. In Kotchen TA, Kotchen JM, Wright J (eds). High Blood Pressure in the Young. PS G: Boston, 1983, pp 79-90.
17. Hoosen S, Seedat YK, Bhigjee AL, Neerahoo RM. A study of urinary sodium and potassium excretion rates among urban and rural Zulus and Indians. J Hypertens 1985; 63: 351-358.
18. Luft FC, Weinberger MH, Grim CE. Sodium sensitivity and resistance in normotensive humans. Am J Med 1982; 72: 726-736.
19. Adlin EV, Marks AD, Channik BJ. The salivary sodium/potassium ratio in hypertension: relation to race and plasma renin activity. Clin Exp Hypertens 1982; 4: 1869-1880.
20. Milne FJ et al. Spot urinary electrolyte concentrations and 24 hour excretion. Lancet 1980; 2: 1135.
21. Grim CE, Henry JP, Myers H. High blood pressure in blacks: salt, slavery, survival, stress and racism. In: Laragh JH, Brenner BM (eds). Hypertension: Pathophysiology, Diagnosis, and Management. Raven Press: New York, 1995, 2nd edn. pp 171-207.
22. Levy SB, Frigon RF, Stone MA. Plasma dopamine β-hydroxylase activity and blood pressure variability in hypertensive man. Clin Endocrinol 1985; 11: 187-199.
23. Schwab EH, Curb DL, Matthewa JL, Schulze VE. Blood pressure response to a standard stimulus in the white and Negro races. Proc Soc Exp Biol Med 1935; 32: 583-585.
24. Light KC et al. Effect of race and marginally elevated blood pressure on response to stress. Hypertension 1987; 10: 555-563.
25. Falkner B, Kushner H, Onesti G, Angelakos ET. Cardiovascular characteristics in adolescents who develop essential hypertension. Hypertension 1981; 3: 521-527.
26. Dimsdale JE et al. Age, race diagnosis, and sodium effects on the pressor response to infused norepinephrine. Hypertension 1987; 10: 564-569.
27. Boyle E Jr. Biological patterns in hypertension by race, sex, body weight, and skin colour. JAMA 1970; 213: 1637-1643.
28. Harburg E et al. Skin color, ethnicity, and blood pressure 1: Detroit blacks. Am J Public Health 1978; 68: 1177-1183.
29. Miller JM. Duffy antigens and hypertension in a black population. Am J Public Health 1985; 75: 558-559.
30. Miall WE et al. Factors influencing arterial pressure in the general population in Jamaica. Br Med J 1962; 2: 497-506.
31. Seedat YK, Seedat MA, Hackland DBT. Prevalence of hypertension in the urban and rural Zulu. J Epidemiol Commun Health 1982; 36: 256-261.
32. Tyroler HA. Socio-economic status, age and sex in the prevalence and prognosis of hypertension in blacks and whites. In: Laragh JH, Brenner MB (eds). Hypertension: Pathophysiology, Diagnosis and Management. Raven Press: New York, 1990, pp 159-174.
33. Campese VM, Parise M, Karubian F, Bigazzi R. Abnormal renal hemodynamics in black salt-sensitive patients with hypertension. Hypertension 1991; 18: 805-812.
34. Walker WG et al. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. JAMA 1992; 268: 3085-3091.
35. Messerli FH, Schmieder RE. Use of diuretic agents in obese or black patients with systemic hypertension. Am J Cardiol 1986; 58: 11A-14A.
36. Burke GL et al. Blood pressure and echocardiographic measures in children: the Bogalusa Heart Study. Circulation 1987; 75: 106-114.
37. Hammond IW et al. Contrast in cardiac anatomy and function between black and white patients with hypertension. J Natl Med Assoc 1984; 76: 247-255.
38. Akinkugbe OO. High Blood Pressure in the African. 1st edn. Churchill Livingstone: Edinburgh, 1972, p 12.
39. William RA. Coronary heart disease in blacks. In: Hall WD, Saunders E, Shulman N (eds). Hypertension in Blacks. Year Book Medical Publishers: Chicago, 1985, pp 71-82.
40. Seedat YK, Mayet FGH, Joubert G. Study of risk factors leading to coronary heart disease in urban Zulus. J Hum Hypertens 1993; 7: 529-532.
41. Veterans Administration Cooperative Study on Antihypertensive Agents: Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. 1. Results of short-term titration with emphasis on racial differences in response. JAMA 1982; 248: 1996-2003.
42. Moser M, Lunn J. Responses to captopril and hydrochlorothiazide in black patients with hypertension. Clin Pharmacol Ther 1982; 32: 307-312.
43. Seedat YK, Hoosen S, Bhigjee AL. Reserpine plus hydrochlorothiazide and sotalol plus hydrochlorothiazide in black and Indian Hypertensive patients. S Afr Med J 1984; 65: 915-917.
44. Seedat YK. Varying responses to hypotensive agents in different racial groups: black versus white differences. J Hypertens 1989; 7: 515-518.
45. Seedat YK. Trial of atenolol and chlorothalidone in black Africans. Br Med J 1980; 281: 1241-1243.
46. Richardson DW et al. Effect of propranolol on elevated arterial blood pressure. Circulation 1968; 37: 534-542.
47. Johnson JA, Burlew BS. Racial differences in propranolol pharmacokinetics. Clin Pharm Ther 1992; 51: 495-500.
48. Holland OB, Fairchild C. Renin classification for diuretic and beta blocker treatment of black hypertensive patients. J Chron Dis 1982; 35: 179-182.
49. Warren SE, O'Connor DT. Does a renal vasodilator system mediate racial differences in essential hypertension? Am J Med 1980; 69: 425-429.
50. Seedat YK. Labetalol hydrochloride in the treatment of black and Indian hypertensive patients. Med Proc 1979; 25: 53-57.
51. Flamenbaum W. Propranolol versus labetalol: interesting differences in efficacy. J Natl Med Assoc 1985; 77 (Suppl): 14-29.
52. Seedat YK, Naiker IP. Efficacy of carvedilol in hypertensive black patients: a pilot study. Curr Ther Res 1993; 54: 753-757.
53. Fadayomi MO, Akinroye KK, Ajao RO, Awosika LA. Monotherapy with nifedipine for essential hypertension, in adult blacks. J Cardiovasc Pharmacol 1986; 8: 466-469.
54. Moser M, Lunn J, Materson BJ. Comparative effects of diltiazem and hydrochlorothiazide in blacks with systemic hypertension. Am J Cardiol 1985; 56: 101H-104H.
55. Leary WP, Asmal AC. Treatment of hypertension with verapamil. Curr Ther Res 1979; 25: 747-752.
56. M'Buyamba-Kabangu JR et al. Intracellular sodium and the response to nitrendipine or atenolol in African blacks. Hypertension 1988; 11: 100-105.
57. Cruickshank JK et al. Treating hypertension in black compared with white non-insulin dependent diabetics: a double-blind trial of verapamil and metoprolol. BMJ 1988; 297: 1115-1159.
58. Materson BJ et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N Engl J Med 1993; 328: 914-921.
59. Parag KB, Seedat YK. Do angiotensin-converting enzyme inhibitors work in black hypertensives? A Review. J Hum Hypertens 1990; 4: 450-452.
60. Ikeda LS et al. Comparative antihypertensive effects of Iosartan 50 mg and losartan 50 mg titrated to 100 mg in patients with essential hypertension. Blood Press 1997; 6: 35-43.
61. Gradman AH et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995; 25: 1345-1350.
62. Ruilope LM et al. Comparative effects of combination drug therapy regimes commencing with either losartan potassium, on angiotensin II receptor antagonist, or enalapril maleate for the treatment of severe hypertension. Blood Press 1996; 5: 32-40.
63. 1) receptor anatagonist: a review of its efficacy and safety in essential hypertension. Pharmacol Ther 1997; 74: 181-194.
64. Anonymous. United States Renal Data System 1992 Annual Data Report. Analytical method: technical notes. Am J Kid Dis 1992; 20 (Suppl 2): 100-107.
65. US Renal Data System. USRDS 1994 Annual Data Report. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Disease, 1994. (NIH Publications No. 94-3176).
66. MacMahon SW, Cutler JA, Furberg CD, Payne GH. The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized controlled trials. Prog Cardiovasc Dis 1986; 29 (Suppl 1): 99-118.
67. Collins R et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990; 335: 827-38.
68. SADTR Report 1994. Combined Report on Maintenance Dialysis and Transplantation in the Republic of South Africa. Du Toit ED, Pascoe M, Mac Gregor K, Thomson PD (eds). Observatory, Cape Town, South Africa.
69. Hannedouche T et al. Randomized controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. BMJ 1994; 309; 833-837.
70. Bohlen L, de Courten M, Weidmann P. Comparative study of the effect of ACE-inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens 1994; 7: 84S-92S.
71. Bakris GL, Griffin KA, Picken MM, Bidani AK. Combined effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on renal injury. J Hypertens 1997; 15: 1181-1185.
72. Ritz E, Orth SR, Strzelczyk P. Angiotemsin converting enzyme inhibitors, calcium channel blockers, and their combination in the treatment of glomerular disease. J Hypertens 1997; 15 (Suppl 2): S21-S26.
73. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-2446.
74. Seedat YK. The stepped-care approach to the treatment of hypertension in black patients. S Afr Med J 1982; 62: 1033-1035.
75. Freis ED. Angiotensin converting enzyme inhibition in clinical practice. Choice of initial treatment. J Cardiovasc Pharmacol 1985; 7: S112-S116.
76. Weir MR, Saunders E. Pharmacologic management of systemic hypertension in blacks. Am J Cardiol 1988; 61: 46H-52H.
77. Report of the Joint National Committee on Detection, Evaluation of High Blood Pressure: A Cooperative Study. JAMA 1977; 237: 255-261.
78. Saunders E. Drug treatment for the hypertensive black patient. J Fam Pract 1988; 26: 659-664.
79. Seedat YK. Perspective of hypertension in black patients; black vs white differences. J Cardiovasc Pharmacol 1990; 16 (Suppl 7); S67-S70.